January 19, 2016 / 4:22 PM / 2 years ago

BUZZ-Aeterna Zentaris Inc: Will complete late-stage study by year end

** Canadian drug developer’s U.S.-listed shares up 27 pct at $3.39; Toronto-listed shares also gain 27 pct to C$4.88

** Says will complete by year-end a confirmatory late-stage trial of its drug for evaluating growth hormone deficiency

** Says it believes the study meets FDA and European regulators’ design expectations for approval

* Expects to submit application for U.S. approval by mid-year 2017, if the study is successful

** Up to Friday’s close, the U.S.-listed stock had fallen about 95 pct in the past 12 months

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below